INVENTIVA.
company in the Czech Republic
- Reports this week
- 0
- Active events
- 1
- Connections
- 34
What's happening
Active this week
Earlier this month
-
INVENTIVA, a company focusing on MASH therapies, held leadership conferences in New York City and Brussels.Some support8 reports
-
Inventiva seeks FDA approval for lanifibranor in the U.S. market.Some support2 reports
-
INVENTIVA appointed Chris Benecchi as COO on August 31, 2026.Some support2 reports
One to three months ago
Gone quiet
No new reports in 90+ days-
INVENTIVA, headquartered in Dijon, announced it is receiving growth funding of €43m in a larger €130m funding round.Some support1 report
-
Inventiva maintained a Buy rating on its MASH lead asset, which can be used in conjunction with GLP-1s, while noting benefits from Trump-era tariffs.Speculative1 report
-
Several conferences, including Jefferies and EASL, were scheduled to take place in Barcelona on May 26, 2026.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around INVENTIVA this week
News at the entities that move INVENTIVA most-
mash StructuralWave Life Sciences is developing WVE-007, an investigational GalNAc-siRNA product, for MASH indications.Moves INVENTIVA
-
Truist Financial Mentioned togetherBank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.Moves INVENTIVA
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves INVENTIVA
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves INVENTIVA
-
European Investment Bank TransactionalThe European Investment Bank (EIB) is seeking investment opportunities in Azerbaijan and focusing on the South Caucasus region.Moves INVENTIVA
-
MarketBeat Mentioned togetherMarketBeat aggregates data on IDT Corporation stock performance.Moves INVENTIVA
Connections
The 14 strongest of 34, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
mash Structural
INVENTIVA focuses on developing therapies and biomarkers specifically targeting MASH.
-
Chris Structural
INVENTIVA employs Chris as Chief Operating Officer.
-
Nasdaq Structural
INVENTIVA is formally listed on the Nasdaq stock exchange.
-
European Investment Bank Transactional
The European Investment Bank issued new warrants and restructured debt with Inventiva.
-
FDA Structural
INVENTIVA relies on the FDA for regulatory approval of lanifibranor to enter the U.S. market.
-
Truist Financial Mentioned together
Truist Financial initiated and maintained stock coverage and ratings for Inventiva.
-
BNP Paribas Mentioned together
The two entities were co-located at the Portzamparc conference.
-
Barcelona Shared context
The company is contextually linked to the city as the location for the EASL Congress.
Show all 14 connections
-
New York Shared context
INVENTIVA is based in New York, which hosts its conference.
-
Cantor Fitzgerald Operational
Cantor Fitzgerald has begun to cover Inventiva, indicating a professional market awareness of the company's activities.
-
MarketBeat Mentioned together
MarketBeat aggregates financial data and reports stock ratings for INVENTIVA.
-
New York City Shared context
INVENTIVA conducts business operations, reporting, and management activities within New York City.
-
London Shared context
Inventiva is contextually linked to London, likely as its base of operations or primary market.
-
Dijon Shared context
INVENTIVA is headquartered in Dijon, France.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
1 eventJune 2026
6 events- MarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.
- INVENTIVA, a company focusing on MASH therapies, held leadership conferences in New York City and Brussels.
- INVENTIVA listed on the Nasdaq stock exchange on May 26, 2026, with upcoming conference plans in New York and Barcelona.
- INVENTIVA, headquartered in Dijon, announced it is receiving growth funding of €43m in a larger €130m funding round.
- Inventiva maintained a Buy rating on its MASH lead asset, which can be used in conjunction with GLP-1s, while noting benefits from Trump-era tariffs.
- Several conferences, including Jefferies and EASL, were scheduled to take place in Barcelona on May 26, 2026.